Clinical Trials
11 trialsNCT06086340 2025-11-18
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Pfizer
Completed
NCT01814397 2024-02-07
Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients
University of Michigan Rogel Cancer Center
Completed
NCT01896050 2016-06-28
LOGRIBMET
University of Michigan Rogel Cancer Center
Completed
NCT01047358 2015-10-08
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer
Pfizer
Completed
NCT01121549 2014-01-22
A Non-Interventional Study With AromasinĀ® As Adjuvant Treatment Of Invasive Early Breast Cancer
Pfizer
Terminated
NCT00776659 2013-11-19
An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin
Pfizer
Terminated
NCT01239745 2012-10-31
AromasinĀ® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer
Pfizer
Terminated
NCT01155063 2012-10-01
Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients
Pfizer
Terminated
NCT01305239 2012-04-10
ETAPE
Pfizer
Terminated
NCT01050634 2010-07-23
FAST
Pfizer
Completed
NCT00932165 2010-07-20
Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin
Pfizer
Completed